Fexuprazan with blood thinners for atrial fibrillation
Treatments studied
Part of Digestive system, Heart & circulation clinical trials.
This study tests whether adding fexuprazan, a stomach-protecting medicine, to standard blood thinners reduces stomach bleeding in people with atrial fibrillation who are at higher risk for bleeding. It aims to see if this combination is safer and still effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have atrial fibrillation, a type of irregular heartbeat.
- You are taking or starting a blood thinner called a NOAC (like apixaban, rivaroxaban, dabigatran, or edoxaban).
- You have at least one factor that increases your risk of stomach bleeding, such as being 75 or older, having kidney disease, taking aspirin or other antiplatelet drugs, using pain relievers like ibuprofen, having had a stomach ulcer or bleeding before, or having a high bleeding risk score.
- You do not have active stomach bleeding, severe liver disease, or a life expectancy of less than one year.
- You are not already required to take a similar stomach-protecting drug (PPI) long-term.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This trial compares two ways to manage blood-thinning medications after a successful atrial fibrillation ablation, specifically for people who also have a heart stent. It aims to find the safest and most effective strategy to prevent strokes and bleeding.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Hear when a new Upper Gastrointestinal Bleeding (UGIB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.